Theraclion sells the CE-marked EchoPulse ultrasound device and one-time use EPack skin cooling system to treat benign but troublesome breast fibroadenomas (lumps) and palpable thyroid nodules. EchoPulse leaves no ugly scars and carries zero infection risk. Its innovation, Beamotion, speeds up therapy. US clinical trials are underway with possible marketing rom 2019. In 2015, Theraclion sold or leased 12 systems for evaluation, mainly in Germany and Asia. In 2016, management expects to sell at
26 Feb 2016
Fast-moving focus
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Fast-moving focus
Theraclion SA (ALTHE:PAR) | 0 0 0.7% | Mkt Cap: 30.8m
- Published:
26 Feb 2016 -
Author:
Dr John Savin -
Pages:
12
Theraclion sells the CE-marked EchoPulse ultrasound device and one-time use EPack skin cooling system to treat benign but troublesome breast fibroadenomas (lumps) and palpable thyroid nodules. EchoPulse leaves no ugly scars and carries zero infection risk. Its innovation, Beamotion, speeds up therapy. US clinical trials are underway with possible marketing rom 2019. In 2015, Theraclion sold or leased 12 systems for evaluation, mainly in Germany and Asia. In 2016, management expects to sell at